Powered by
Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model

Regenacy Pharmaceuticals, LLC , a clinical-stage biopharmaceutical company that is regenerating biological function by selective protein acetylation, today announced the publication of data demonstrating reversal of chemotherapy-induced peripheral neuropathy after treatment with HDAC6 inhibitors including ricolinostat in a preclinical model. The article , titled "HDAC6 Inhibition Effectively Reverses Chemotherapy-Induced Peripheral Neuropathy," was published online in PAIN, the official Journal

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox